Keloids and post surgical hypertrophic scars keloid, verapamil, triamcinolone acetonide
Conditions
Interventions
Group A will receive a combination of triamcinolone acetonide (20mg/ml) and Verapamil (1.25mg/ml) ,Group B will receive intralesional injections of triamcinolone acetonide (20 mg/ml).
Active Comparator Drug,Active Comparator Drug
Group A,Group B
Sponsors
Muhammad Tayyab Iqbal
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1 Patients with post-surgical keloid scars 2 Age range of 18-55 years 3 Both male and female patients
Exclusion criteria
Exclusion criteria: 1 Patients who have already received treatment of keloids within 2 months 2 Keloids on head and neck area 3 Keloid size <0.5 cm or >10 cm 4 Pregnant or lactating women 5 Known allergy to verapamil or triamcinolone 6 Patients with comorbid like ischemic heart disease, diabetes mellitus, hypertension, immunocompromised status, Chronic liver or kidney failures 7 Patients with active infection around the keloid area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| post inflammatory hyperpigmentation 3 months Vancouver scar scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Telangiectasia, Skin Atrophy 3 months Vancouver scar scale,pain 1 month pain scale | — |
Countries
Pakistan
Contacts
Public ContactTayyab Iqbal
Pak Emirates military hospital Rawalpindi
Outcome results
None listed